MX2017012775A - Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. - Google Patents

Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.

Info

Publication number
MX2017012775A
MX2017012775A MX2017012775A MX2017012775A MX2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A
Authority
MX
Mexico
Prior art keywords
hig
antibody
luk
staphylococcus aureus
combination preparation
Prior art date
Application number
MX2017012775A
Other languages
English (en)
Inventor
Nagy Eszter
Rouha Harald
Stulik Lukas
Visram Zehra
Badarau Adriana
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of MX2017012775A publication Critical patent/MX2017012775A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una preparación combinatoria de anticuerpos anti-Staphylococcus aureus, que comprende a) un anticuerpo con neutralización cruzada de toxinas, que comprende por lo menos un sitio de unión poliespecífico que se une a toxina alfa (HIa) y por lo menos una de las toxinas de dos componentes seleccionadas de entre el grupo que consiste en HIgAB, HIgCB, LukSF, LukED, LukS-HlgB, LukSD, HIgA-LukD, HIgA-LukF, LukEF, LukE-HIgB, HlgC-LukD y HIgC-LukF; y b) un anticuerpo anti-LukGH; y/o c) un anticuerpo de OPK que reconoce una proteína de superficie de S. aureus, lo que en consecuencia induce OPK, específicamente un anticuerpo anti-proteína de unión a lg (IGBP) que comprende por lo menos un sitio de unión de CDR que reconoce a cualquiera de los dominios de unión a lgG de la Proteína A o Sbi de S. aureus.
MX2017012775A 2015-04-17 2016-04-14 Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. MX2017012775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15164000 2015-04-17
PCT/EP2016/058240 WO2016166223A1 (en) 2015-04-17 2016-04-14 Anti-staphylococcus aureus antibody combination preparation

Publications (1)

Publication Number Publication Date
MX2017012775A true MX2017012775A (es) 2019-04-29

Family

ID=52997891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012775A MX2017012775A (es) 2015-04-17 2016-04-14 Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.

Country Status (12)

Country Link
US (1) US20180179267A1 (es)
EP (1) EP3283514A1 (es)
JP (1) JP2018513168A (es)
KR (1) KR20170136637A (es)
CN (1) CN107873034A (es)
AU (1) AU2016249837A1 (es)
BR (1) BR112017021779A2 (es)
CA (1) CA2978855A1 (es)
IL (1) IL255062A0 (es)
MX (1) MX2017012775A (es)
RU (1) RU2017139800A (es)
WO (1) WO2016166223A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
CA2925071A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
BR112021006622A2 (pt) * 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022212667A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
US8709980B2 (en) 2007-03-26 2014-04-29 Celexion, Llc Cell surface display, screening and production of proteins of interest
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009088924A2 (en) * 2007-12-31 2009-07-16 Xoma Technology Ltd. Methods and materials for targeted affinity enhancement
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
AU2012273125B2 (en) * 2011-06-19 2017-05-25 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide
BR112013032774B1 (pt) * 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2793944B1 (en) * 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
AU2013251165B2 (en) * 2012-04-17 2017-08-24 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
US20160074497A1 (en) 2013-05-03 2016-03-17 The University Of Chicago Staphylococcus live cell vaccines
RU2015154792A (ru) * 2013-05-21 2017-06-22 Арзанис Байэусайнсис ГмбХ Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus
CA2925071A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
WO2015091935A2 (en) * 2013-12-19 2015-06-25 Arsanis Biosciences Gmbh Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
KR20170137111A (ko) * 2015-04-17 2017-12-12 알사니스 바이오사이언시스 게엠베하 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤

Also Published As

Publication number Publication date
WO2016166223A1 (en) 2016-10-20
US20180179267A1 (en) 2018-06-28
BR112017021779A2 (pt) 2018-07-10
RU2017139800A (ru) 2019-05-17
CA2978855A1 (en) 2016-10-20
IL255062A0 (en) 2017-12-31
AU2016249837A1 (en) 2017-09-28
JP2018513168A (ja) 2018-05-24
KR20170136637A (ko) 2017-12-11
EP3283514A1 (en) 2018-02-21
CN107873034A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
FR23C1012I2 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
PH12017500890A1 (en) Antibody drug conjugates
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
MX377753B (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
PH12016501366A1 (en) Novel anti-baff antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
BR112017021779A2 (pt) ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
MX2021003685A (es) Inhibicion dirigida del factor de crecimiento transformador b (tgfb).
MX375402B (es) Nuevo anticuerpo anti-dengue de espectro completo.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201590918A1 (ru) Антитела к bmp-6
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA201990222A1 (ru) Антитела к o2 и пути их применения
EA201992315A1 (ru) Композиции и способы для лечения рака легкого